TITLE

Sarcoidosis in HIV-Infected Patients in the Era of Highly Active Antiretroviral Therapy

AUTHOR(S)
Foulon, Guillaume; Wislez, Marie; Naccache, Jean-Marc; Blanc, François-Xavier; Rabbat, Antoine; Israël-Biet, Dominique; Valeyre, Dominique; Mayaud, Charles; Candranel, Jacques
PUB. DATE
February 2004
SOURCE
Clinical Infectious Diseases;2/1/2004, Vol. 38 Issue 3, p418
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
To analyze the impact of highly active antiretroviral therapy (HAART) on the characteristics and outcome of sarcoidosis in patients infected with human immunodeficiency virus (HIV), we identified HIV-infected patients in whom sarcoidosis was diagnosed between 1996 and 2000 from the admission registers of the pneumology departments of 12 hospitals in the Paris region (France). Sarcoidosis was diagnosed in 11 HIV-infected patients, of whom 8 were receiving HAART. HIV infection was diagnosed before sarcoidosis in 9 cases. At diagnosis of sarcoidosis, the mean CD4 cell count (±SD) was 390 ± 213 cells/mm³, and the mean plasma virus load was 4002 ± 10,183 copies/mL. Sarcoidosis occurred several months after HAART introduction, when the CD4 cell count had increased and the plasma HIV load had decreased. Clinical and radiological characteristics, laboratory values for bronchoalveolar lavage fluid samples, and outcome after a long follow-up were similar for the patients receiving HAART and for HIV-uninfected patients.
ACCESSION #
12080479

 

Related Articles

  • Delayed Progression to Death and to AIDS in a Hong Kong Cohort of Patients with Advanced HIV Type 1 Disease During the Era of Highly Active Antiretroviral Therapy. Ka Hing Wong; Kenny Chi Wai Chan; Shui Shan Lee // Clinical Infectious Diseases;9/15/2004, Vol. 39 Issue 6, p853 

    Background. The magnitude of the impact of highly active antiretroviral therapy (HAART) since its introduction in non-Western countries is not entirely clear. We studied disease progression among adult patients with advanced human immunodeficiency virus type 1 (HIV-1) infection in the pre-HAART...

  • Plasma HIV Load and Proviral DNA Decreases After Two Standard Antiretroviral Regimens in HIV-Positive Patients Naive to Antiretrovirals. Torti, Carlo; Quiros-Roldan, Maria Eugenia; Cologni, Giuliana; Nichelatti, Michele; Ceresoli, Francesca; Pinti, Marcello; Nasi, Milena; Cossarizza, Andrea; Lapadula, Giuseppe; Costarelli, Silvia; Manca, Nino; Gargiulo, Franco; Magoni, Michele; Carosi, Giampiero // Current HIV Research;Jan2008, Vol. 6 Issue 1, p43 

    (i) To compare early decrease of HIV plasma viral load (pVL) after two standard combinations of highly active antiretroviral therapy (HAART). (ii) To evaluate variations of proviral HIV-DNA load on conditions of sustained pVL undetectability. Two different sub-studies of a multicentre...

  • Antiretroviral Drugs in Pediatric HIV-Infected Patients. Phelps, B. Ryan; Rakhmanina, Natella // Pediatric Drugs;2011, Vol. 13 Issue 3, p175 

    Antiretroviral (ARY) therapy has been shown to achieve high therapeutic efficacy in treating pediatric HLV disease. The delivery of affordable, child friendly, and easy to store and administer ARV drugs is key to the successful management of HIV in children. In recent years, significant progress...

  • CCL3L1-CCR5 genotype influences durability of immune recovery during antiretroviral therapy of HIV-1–infected individuals. Ahuja, Sunil K.; Kulkarni, Hemant; Catano, Gabriel; Agan, Brian K.; Camargo, Jose F.; Weijing He; O'Connell, Robert J.; Marconi, Vincent C.; Delmar, Judith; Eron, Joseph; Clark, Robert A.; Frost, Simon; Martin, Jeffrey; Ahuja, Seema S.; Deeks, Steven G.; Little, Susan; Richman, Douglas; Hecht, Frederick M.; Dolan, Matthew J. // Nature Medicine;Apr2008, Vol. 14 Issue 4, p413 

    The basis for the extensive variability seen in the reconstitution of CD4+ T cell counts in HIV-infected individuals receiving highly active antiretroviral therapy (HAART) is not fully known. Here, we show that variations in CCL3L1 gene dose and CCR5 genotype, but not major histocompatibility...

  • Immune reconstitution syndrome leading to fatal invasive cerebral aspergillosis: case report.  // Reactions Weekly;7/16/2005, Issue 1060, p6 

    The article presents a case of an HIV-infected man with fatal invasive cerebral aspergillosis associated with immune reconstitution syndrome after starting antiretroviral therapy. The man received other medical treatment after weeks of antiretroviral therapy. Medical history and condition of the...

  • Barriers to Initiation of Antiretrovirals during Antituberculosis Therapy in Africa. Pepper, Dominique J.; Marais, Suzaan; Wilkinson, Robert J.; Bhaijee, Feriyl; De Azevedo, Virginia; Meintjes, Graeme // PLoS ONE;2011, Vol. 6 Issue 5, p1 

    Background: In the developing world, the principal cause of death among HIV-infected patients is tuberculosis (TB). The initiation of antiretroviral therapy (ART) during TB therapy significantly improves survival, however it is not known which barriers prevent eligible TB patients from...

  • Lymphocyte subsets and viral load in patients with HIV-associated non-Hodgkin's lymphoma treated with anti-CD20 monoclonal antibody and chemotherapy. De Paoli, P.; Vaccher, E.; Tedeschi, R.; Caffau, C.; Zanussi, S.; Bortolin, M. T.; Crepaldi, C.; Spina, M.; Tirelli, U. // Cancer Immunology, Immunotherapy;May2001, Vol. 50 Issue 3, p157 

    The anti-CD20 monoclonal antibody Rituximab is a novel antitumor agent used in association with chemotherapy (CT) for the treatment of high-grade/intermediate non-Hodgkin's lymphomas (NHL) in HIV-negative populations. This therapeutic combination is currently also being explored in HIV-positive...

  • Risk Factors for Nevirapine-Associated Rash Among HIV-Infected Patients with Low CD4 Cell Counts in Resource-Limited Settings. Kiertiburanakul, Sasisopin; Sungkanuparph, Somnuek; Charoenyingwattana, Angkana; Mahasirimongkol, Surakameth; Sura, Thanyachai; Chantratita, Wasun // Current HIV Research;Jan2008, Vol. 6 Issue 1, p65 

    Nevirapine (NVP) is commonly used as a component of first-line antiretroviral therapy in resource-limited countries. We aimed to determine the risk factors for NVP-associated rash among HIV-infected patients who were initiated NVP at low CD4 cell counts in a resource-limited setting. A...

  • Valaciclovir versus aciclovir for herpes simplex virus infection in HIV-infected individuals: two randomized trials. Conant, M. A.; Schacker, T. W.; Murphy, R. L.; Gold, J.; Crutchfield, L. T.; Crooks, R. J.; International Valaciclovir HSV Study Group // International Journal of STD & AIDS;Jan2002, Vol. 13 Issue 1, p12 

    Our objective was to evaluate valaciclovir for anogenital herpes in HIV-infected individuals using 2 controlled trials conducted before highly active antiretroviral therapy (HAART) was used. In Study 1, 1062 patients (CD4+ > or = 100 cells/mm(3)) received suppressive valaciclovir or aciclovir...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics